WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, a global leader in innovative drug discovery services, announces the achievement of a drug discovery milestone, following a partner’s attainment of a development candidate. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, utilized X-Chem’s DNA-Encoded Library (DEL) platform to perform hit finding intended to discover molecules with differentiated pharmacological properties. The resulting molecule led to a development candidate — a milestone under the companies’ collaboration agreement and to progress in evaluation.
X-Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science
X-Chem Appoints Chief Scientific Officer and Chief Financial Officer
X-Chem and Kymera Expand Existing Partnership
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the global leader in DNA-encoded library (DEL) technology, today announces the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline. Through the collaboration, X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
SHANGHAI--(BUSINESS WIRE)--BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its powerful DEL technology platform and large collection of novel, diverse lead- and drug-like small molecule compounds to help customers significantly accelerate the discovery of hits and expand their target range. Combined with BioDuro-Sundia's one-stop drug discovery platform, customers can access world-class discovery technologies and support, covering hit identification and optimization, evaluation of lead and candidate compounds, and quickly advance to preclinical development.
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the leader of DNA-encoded library (DEL) technology and artificial intelligence (AI) for small molecule drug discovery, today announced the availability of XD3 — X-Chem’s Dynamic Drug Discovery ecosystem for biopharma partners and clients. XD3 combines the vast trove of data generated by DEL screening, the analytical and predictive power of X-Chem’s artificial intelligence platform, ArtemisAI, and its deep medicinal chemistry expertise into an end-to-end package designed to accelerate the path to new medicines.
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the pioneer of DNA-encoded library (DEL) technology and artificial intelligence (AI) for small molecule drug discovery, today announced that Senior Vice President and General Manager Noor Shaker was named a winner in the Artificial Intelligence Excellence Awards program from Business Intelligence Group. Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems.
LONDON and HYDERABAD, India, Feb. 9, 2022 /PRNewswire/ -- A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets.
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery. Coupling X-Chem’s high-quality DEL data with the innovative AI capabilities of Glamorous AI positions X-Chem as a leading service provider in machine learning-driven drug discovery.